Ubidecarenone

Drug Profile

Ubidecarenone

Alternative Names: Bio-Quinone Q10; Coenzyme Q10; CoQ10; Neuquinon; Q-Gel; UbiQGel; Ubiquinone; Vitaline; Vitaline CoQ10

Latest Information Update: 19 Apr 2006

Price : $50

At a glance

  • Originator Eisai Co Ltd; Enzymatic Therapy; Nonindustrial source; Pharma Nord; Tishcon Corporation
  • Developer Enzymatic Therapy; Pharma Nord; Tishcon Corporation
  • Class Antineoplastics; Benzoquinones; Cardiotonics; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure
  • Discontinued Fibromyalgia; Huntington's disease; Immunodeficiency disorders; Metabolic disorders; Myocardial infarction; Neurological disorders; Parkinson's disease; Reperfusion injury; Stroke

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Apr 2006 Phase-I clinical trials in Neurological disorders in USA (PO)
  • 19 Apr 2006 Data presented at the 58th Annual Meeting of the American Academy of Neurology (AAN-2006) have been added to the adverse events and Neurological disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top